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g/10.1016Abstract Autism is a neurodevelopment disorder. Its aetiology and pathophysiology are not clearly
known. However, mitochondria may play a signiﬁcant role at least in some cases of autism. There is
no therapeutic approach for autism. Moreover, there are only few Food and Drug Administration
(FDA)-approved medications for autism. Therefore, providing novel therapeutic approaches are
highly required. Oxidative stress is suggested as an important factor in the aetiology of autism.
Already some interventions targeting oxidative stress in autism are suggested.
This article reviews evidence about the possible role of gold nanoparticles and lipoic acid (LA) as
anti-inﬂammatory agents. It mentions some evidence about the possible role of oxidative stress.
Then, the role of gold nanoparticles and LA for the management of autism is discussed.
According to the above-mentioned evidence, it is hypothesised that gold nanoparticles and LA
may reduce neuro-inﬂammation in autism.
Controlled experimental studies are needed to test whether gold nanoparticles plus LA enhance
antioxidative stress system leading to the improvement of autism clinical symptoms.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license. Introduction
Gold nanoparticles increase cutaneous wound healing in
mouse through its anti-inﬂammatory and antioxidative effects
[1]. Moreover, gold implants and the increased expression of
metallothionein-I/II are suggested as possible therapeutic ap-
proach for autism [2]. According to the following evidence,.ir
niversity of Medical Sciences. Pub
h/
/j.jmhi.2012.03.004gold nanoparticles plus lipoic acid (LA) may be a hypothesised
treatment for autism symptoms. Other interventional ap-
proaches such as gold implants [2], targeting of nuclear factor
kappa B (NF-jb) [3], olesoxime [4], zonisamide [5], ziconotide
[6], c-Kit+ cell transplantation [7] and the targeting of glycine
site on N-methyl-D-aspartate (NMDA) receptor [8] are also
suggested to tackle oxidative stress in autism.lished by Elsevier Ltd. Open access under CC BY-NC-ND license. 
Figure 1 The proposed effect of lipoic acid on oxidative stress in autism.
Gold nanoparticles and lipoic acid as a novel anti-inﬂammatory 41The role of LA in mitochondrial dehydrogenase reactions is
crucial. A disulphide bond attaches two sulphur atoms of LA.
LA can be oxidised. Dihydrolipoic acid is the reduced form of
LA with pharmacological beneﬁts. It is an important cofactor
for mitochondrial enzymes of pyruvate dehydrogenase (PDH)
and a-ketoglutarate dehydrogenase (KGDH). LA is a possible
modulator of redox status in cells [9]. LA reacts with reactive
oxygen species (ROS) including superoxide radicals, hydroxyl
radicals, peroxyl radicals and singlet oxygen.
LA is suggested for the treatment of oxidative stress-associ-
ated problems such as multiple sclerosis [10] and acute optic
neuritis in humans [11]. a-LA has an anticonvulsant effect
and decreases pilocarpine-induced seizure in animals [12,13].
It inhibits caspase-3-dependent apoptosis through cytochrome
c [12]. Moreover, LA scavenges free radicals and it is suggested
as a reason for lowering seizure susceptibility [13]. In addition,
LA removes ROS and increases the level of reduced glutathi-
one [14]. The improvement of Na+, K+, ATPase activity is
also associated with LA [13]. This enzyme plays an important
role for maintaining the ionic gradient required for neuronal
excitability. Free radicals impair the activity of this enzyme.
a-LA also has anti-inﬂammatory effects. The neuroprotec-
tive effects of a-LA are suggested due to its anti-inﬂammatory
and antioxidant properties [15]. LA reduces the expression of
pro-inﬂammatory proteins such as tumour necrosis factor
(TNF) and inducible nitric oxide synthase [14]. Furthermore,
the anti-inﬂammatory effects of a-LA can be through the inhibi-
tion of NF-jB activation [16].Moreover, the anti-inﬂammatoryeffects of oral administration of LA can be provoked via cyclic
adenosine monophosphate (cAMP) and protein kinase A
signalling [17].
In addition, LA increases the superoxide dismutase and cat-
alase activities [18] and glutathione peroxidase in animal mod-
els (Fig. 1). LA increases cerebral glutathione (GSH) levels. In
addition, LA increases GSH level and glutathione peroxidase
(GSH-Px) activity [13]. Both of them have an important role
in antioxidant function. The inducing of GSH synthesis en-
zymes and other antioxidant protective enzymes by LA are re-
ported [19].
Autism is a disorder that its aetiology and neurobiology are
not clearly known. Oxidative stress is enhanced in autism [20].
Oxidative stress plays a signiﬁcant role in the neurobiology of
autism [21,22] and the targeting of oxidative stress is suggested
as a therapeutic approach [21]. Antioxidant enzymes of super-
oxide dismutase (SOD) and GSH-Px are lower in autism than
the controls [23,24]. In addition, the concentrations of exoge-
nous antioxidants, vitamins E and A, and lycopene in individ-
uals with autism are not sufﬁcient [25].
Impaired mitochondrial energy production has an aetiolog-
ical role for autism too [26]. Moreover, brain inﬂammation is
also associated with autism. Inﬂammation and apoptosis have
important causative roles for autism [27]. Meanwhile, anti-
apoptotic signalling pathway is compromised in the brain in
autism [28]. The expression level of pro-inﬂammatory cyto-
kines TNF-a and interleukin-6 (IL-6) are increased but B-cell
lymphoma (Bcl)2 expression is reduced [27]. The expression
42 A. Ghanizadehof caspase-3, which is an important executioner of apoptosis, is
enhanced in autism [29]. The management of inﬂammation
may play a role in the treatment of autism [30,31]. Fig. 1 shows
the possible role of LA on them.Hypothesis
According to the above-mentioned evidence and the anti-
inﬂammatory effect of LA for treatment of neuritis [11], and
the effect of gold nanoparticles plus LA through anti-inﬂam-
mation and antioxidation effects [1], it seems to be reasonable
to hypothesise that gold nanoparticles and LA can be a novel
treatment for autism too.Evaluation of hypothesis
Therefore, animal model experimental studies are suggested to
test this novel hypothesised treatment. A study with two arms
is suggested. One group will receive gold nanoparticles plus
LA. The other group will receive placebo. There are two types
of outcome measurements. The ﬁrst one assesses the possible
changes in antioxidative stress activity of SOD, GSH-Px and
catalase. In addition, the level of GSH is assessed. The second
type of outcome measurement evaluates the clinical manifesta-
tion of autism in animal models.Discussion
Given that LA has the following effects: scavenges free radicals
[13], increases reduced GSH levels [14], increases SOD and cat-
alase activities [18] and GSH-Px activity, and induces GSH
synthesis enzymes and other antioxidant protective enzymes
[19], and anti-inﬂammatory effects. In the meantime, autism
is a disorder with enhanced oxidative stress [20,33], decreased
antioxidant enzymes of SOD and GSH-Px [23,24], brain
inﬂammation, apoptosis [27], increased the levels of pro-
inﬂammatory cytokines TNF-a and IL-6 [27] and impaired
mitochondrial energy production [26,32]. Therefore, it may
at least partially improve some symptoms of autism. However,
it needs to be noticed that some of ROS have the role of being
as second messengers [34]. So, animal model studies are recom-
mended. Further studies may investigate whether LA and gold
nanoparticles may improve inﬂammation. In addition, it needs
to be answered whether they should be administered together.
The way that they might be administered should be discussed.Conclusion
Considering the neurobiology of autism and the mechanism-
based function of gold nanoparticles plus LA, it is hypothesised
that gold nanoparticles plus LA improve autism symptoms
through the enhancement of defence against oxidative stress.Conﬂict of interest statement
The author has no conﬂicts of interest with regard to the con-
tent of this article.Overview Box
First Question: What do we already know about the
subject?
Autism is a disorder that its aetiology is not clearly
known. Oxidative stress is frequently reported to be
involved in the aetiology of autism. There is no curative
approach for autism. Oxidative stress is hypothesised as
a therapeutic target.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts does
it have?
This theory tries to suppose that gold nanoparticles
and LA as a novel therapeutic approach for the treatment
of autism. It is expected to be effective for at least some of
these patients with oxidative stress.
Third Question: Among numerous available studies,
what special further study is proposed for testing the idea?
Preliminary controlled experimental studies on animal
models of autism are suggested.References
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